KCP2 Inhibitors
Oligosaccharyl transferase subunit KCP2 (KCP2) Inhibitors are chemical compounds that diminish the functional activity of KCP2 through a variety of signaling pathways. Staurosporine, a broad-spectrum kinase inhibitor, blocks the phosphorylation of KCP2, an essential step for its function, which could include the regulation of cell cycle progression or other cellular processes where phosphorylation by kinases is crucial. Similarly, LY 294002 and Wortmannin, both PI3K inhibitors, lead to the decreased activation of Akt, which, if KCP2 is a downstream effector, would result in a reduction of KCP2's phosphorylation and activity. Rapamycin, by inhibiting mTOR, can indirectly impact the phosphorylation status of KCP2 through the mTOR/S6K1 pathway. MEK inhibitors, such as PD 98059 and U0126, target the ERK pathway, and their inhibition could lead to reduced ERK-mediated phosphorylation of KCP2, assuming it's regulated by this pathway, thus hindering KCP2's role in cell signaling.
The functional activity of KCP2 is further influenced by inhibitors targeting other kinases and signaling molecules. SB 203580, a p38 MAPK inhibitor, and SP600125, a JNK inhibitor, both act on stress-activated MAPK pathways, which could involve the phosphorylation of KCP2, leading to its functional inhibition. Triciribine and Dasatinib, which target Akt and Src family kinases respectively, have the potential to prevent the activation of KCP2 if it is associated with Akt signaling or is a substrate of Src kinases. PP 2, by inhibiting Src family kinases and c-Kit, can diminish KCP2 activity if it operates downstream of these kinases. Lastly, Gö 6983 targets protein kinase C, and if KCP2 is a substrate of PKC, Gö 6983 would reduce KCP2's signaling capacity. Collectively, these inhibitors employ a multifaceted approach to impede the phosphorylation and activation of KCP2, thereby attenuating the functional capacity of KCP2 within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent inhibitor of protein kinases. Staurosporine can inhibit KCP2 by preventing its phosphorylation, which is essential for KCP2's function in regulating cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of PI3K, which is upstream of the Akt pathway. By inhibiting PI3K, LY 294002 diminishes the phosphorylation and activation of Akt, resulting in reduced phosphorylation and activity of downstream targets, including KCP2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor which can decrease the activity of S6K1, leading to diminished phosphorylation of substrates, among which KCP2 might be affected due to its potential involvement in mTOR signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that indirectly inhibits the ERK pathway. By inhibiting MEK, PD 98059 reduces ERK-mediated phosphorylation events that could include the phosphorylation of KCP2, leading to its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that can reduce the activity of p38 MAPK, leading to decreased phosphorylation of substrates involved in stress response, which may include KCP2 if it is part of this response. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2, which prevents the activation of ERK1/2. This inhibition may lead to decreased phosphorylation and activation of KCP2 if it is regulated by the ERK1/2 pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A potent inhibitor of PI3K, leading to reduced Akt activity. This effect might extend to KCP2 if it is a downstream effector in the PI3K/Akt pathway, resulting in diminished KCP2 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is involved in the stress-activated MAPK pathway. By inhibiting JNK, SP600125 may decrease the phosphorylation of KCP2 if it is a target of JNK, leading to inhibition of KCP2's function. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
An Akt inhibitor that prevents the phosphorylation and activation of Akt-dependent signaling pathways. If KCP2's activity is modulated through Akt, triciribine's action would result in diminished KCP2 function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A Src family kinase inhibitor that could inhibit the phosphorylation of proteins within various signaling pathways, potentially including KCP2 if it is a Src kinase substrate. | ||||||